臨床研究等提出・公開システム

Date of registration	Dec. 09, 2014
Last modified on	Dec. 17, 2018
Trial ID	jRCT2080222684

Scientific Title	DS-7113b injection phase II/III study An open label and extension study of DS-7113 injection in patients with cancer pain (intravenous administration)
Public Title	DS-7113b injection phase II/III study (intravenous administration)

Completion Date or Terminated date
Actual Enrolled Number
Baseline Characteristics
Participant flow
Adverse events
Primary Outcome Measures
Secondary Outcome Measures
Brief summary
Posting of journal publication
Date of the first journal publication of results
URL hyperlink(s) related to results and publications

Plan to share IPD
Plan description
URL link to protocol file(s)
Version of protocol file(s)	version: date:

Contact for Scientific Queries	Name
	Contact Name for Scientific Queries
	Address
	Phone Number
	E-mail Address

Contact for Public Queries	Name
	Contact Name for Public Queries	DAIICHISANKYO Co.,Ltd.
	Address	http://www.daiichisankyo.co.jp/corporate/rd/measure/clinical/index.html
	Phone Number
	E-mail Address

Recruitment Status

Date of First Enrolment
Target Sample Size
Study Type		Interventional
Study Design	Study Design	A multicenter, open, uncontrolled study
Study Design	Objective
Phase		2-3
Key inclusion & exclusion criteria	Inclusion Criteria	1) Patients who can be hospitalized during a dosage period, and secure a route to carry out intravenous administration 2) Patients receiving analgesics for cancer pain 3) Patients with an ECOG Performance Status (PS) is =< 3, etc.
	Exclusion Criteria	Patients with symptom(s)/finding(s) falling under the contraindications or relative contraindications stated in the package insert for oral oxycodone hydrochloride and morphine hydrochloride, etc.
	Minimum Age	20age old over
	Maximum Age	No limit
	Gender	Both
Health Condition or Problem Studied		Moderate to severe cancer pain
Intervention(s)		investigational material(s) Generic name etc : DS-7113b injection (intravenous administration) INN of investigational material : Hydromorphone hydrochloride Therapeutic category code : 811 Opium alkaloids preparations Dosage and Administration for Investigational material : Continuous intravenous administration for up to 28 days.
Health Condition(s) Keyword
Intervention(s) Keyword
Health Condition(s) Code
Intervention(s) Code
Primary Outcome		Response rate by Day 7 (analgesia improvement rate)
Secondary Outcome		Change of pain intensity (PI) and VAS, efficacy and safety

Primary Sponsor	DAIICHISANKYO Co.,Ltd.
Secondary Sponsor

Name of Funding Organization
Name of Research Funding

Name of IRB
Address of IRB
Phone Number of IRB
E-mail Address of IRB
Status of IRB Review
Date of Approval by IRB

Secondary ID No.	JapicCTI-142735
Name of Other Registries

Countries / Regions of Recruitment

History of Changes

No	Publication date
9	Dec. 17, 2018	(this page)	Changes
8	Oct. 05, 2018	Detail	Changes
7	Oct. 04, 2018	Detail	Changes
6	June. 27, 2016	Detail	Changes
5	June. 27, 2016	Detail	Changes
4	Dec. 17, 2015	Detail	Changes
3	Dec. 17, 2015	Detail	Changes
2	Dec. 09, 2014	Detail	Changes
1	Dec. 09, 2014	Detail

List of change history